In 2024, the U.S. Drug Enforcement Administration (DEA) indicated which they intend to reclassify marijuana for a Agenda III drug. This rescheduling will identify that cannabis has legitimate healthcare functions and can help open up the doorway to investigate on other potential therapy uses.